{"id":46025,"date":"2012-05-31T23:26:58","date_gmt":"2012-05-31T23:26:58","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/n-of-one-announces-agreement-with-foundation-medicine-to-provide-the-first-patient-specific-genomic-diagnostic.php"},"modified":"2012-05-31T23:26:58","modified_gmt":"2012-05-31T23:26:58","slug":"n-of-one-announces-agreement-with-foundation-medicine-to-provide-the-first-patient-specific-genomic-diagnostic","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/n-of-one-announces-agreement-with-foundation-medicine-to-provide-the-first-patient-specific-genomic-diagnostic.php","title":{"rendered":"N-of-One Announces Agreement with Foundation Medicine to Provide the First Patient-Specific Genomic Diagnostic &#8230;"},"content":{"rendered":"<p><p>    WALTHAM, Mass.--(BUSINESS WIRE)--  <\/p>\n<p>    N-of-One, Inc., provider of Diagnostic Strategy Roadmaps and    Treatment Strategy Roadmaps for personalized cancer care, announced    today that the company has entered into a strategic    collaboration with Foundation Medicine, Inc. to support the    development of its fully informative molecular cancer profiles    that can be used to guide individualized patient treatment    strategies.  <\/p>\n<p>    Foundation    Medicine will use its state-of-the-art genomic sequencing and    analytic capabilities on patient tumor samples to detect and    analyze molecular alterations in hundreds of cancer-related    genes to potentially identify biological markers that may be    driving the onset, growth, and spread of an individuals    cancer. N-of-One will apply its PrecisionWorks knowledge    integration platform for personalized medicine to assist in the    transformation of cancer-relevant genomic alteration data    identified by Foundation Medicine into clinically    relevant information by linking each molecular variation with    up-to-date information about relevant targeted therapies and    clinical trials that may be effective against the individuals    tumor. Foundation Medicine provides its reports to oncologists    to help them determine appropriate treatment strategies tailored to each    patient based on their specific genomic profile.  <\/p>\n<p>    This collaboration represents another important step toward    transforming next-generation sequencing into a decision-making    tool that empowers oncologists to act rapidly and decisively in    providing precision treatment strategies for their patients,    said Jennifer Levin Carter, MD, Founder and President of    N-of-One. We are delighted to work with Foundation Medicine to    convert comprehensive cancer-associated molecular data from its    market-leading test into customized reports that will help    physicians optimize treatment strategies and improve patient    outcomes.  <\/p>\n<p>    N-of-One is a leader in the curation of molecular    information, said Kevin Krenitsky, MD, COO of Foundation    Medicine. N-of-One has developed a knowledge integration    platform that will help us translate genomic alteration data    into information that can be provided to clinicians to help    them understand and act upon the genomic data we provide. We    are excited to collaborate with N-of-One to provide our fully    informative genomic profile to benefit patients.  <\/p>\n<p>    About N-of-One  <\/p>\n<p>    N-of-One is dedicated to helping oncologists identify optimal    personalized diagnostic and treatment strategies for each    individual patienteach n of one. Powered by our proprietary    PrecisionWorks knowledge integration platform, the N-of-One    team develops roadmaps that drive highly informed clinical    decision-making by linking data about the molecular variations    in each patients cancer cells with leading-edge knowledge,    diagnostics, treatments, and technologies relevant to the tumor    type. PrecisionWorks also powers solutions that address the    unique logistical and procedural challenges of delivering    personalized cancer care by streamlining coordination among    health care providers, diagnostic companies, payers, drug and    technology innovators, and patients. N-of-One works with    physicians and therefore does not providemedical advice    nor promote any product orservice. For more information,    please visit     <a href=\"http:\/\/www.n-of-one.com\" rel=\"nofollow\">http:\/\/www.n-of-one.com<\/a>.  <\/p>\n<p>    About Foundation Medicine  <\/p>\n<p>    Foundation Medicine is a molecular information company    dedicated to a transformation in cancer care in which treatment    is informed by a deep understanding of the genomic changes that    contribute to each patients unique cancer. The company has    developed a fully informative genomic profile to identify a    patients individual molecular alterations and match them with    relevant targeted therapies and clinical trials. Foundation    Medicines molecular information platform aims to improve    day-to-day care for patients by serving the needs of    clinicians, academic researchers and drug developers to help    advance the science of molecular medicine in cancer. For more    information, please visit the companys website     <a href=\"http:\/\/www.foundationmedicine.com\" rel=\"nofollow\">http:\/\/www.foundationmedicine.com<\/a>.  <\/p>\n<\/p>\n<p>Read the original here: <\/p>\n<p><a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/n-one-announces-agreement-foundation-130000713.html;_ylt=A2KJjagv_sdPK1MA4gX_wgt.\" title=\"N-of-One Announces Agreement with Foundation Medicine to Provide the First Patient-Specific Genomic Diagnostic ...\">N-of-One Announces Agreement with Foundation Medicine to Provide the First Patient-Specific Genomic Diagnostic ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> WALTHAM, Mass.--(BUSINESS WIRE)-- N-of-One, Inc., provider of Diagnostic Strategy Roadmaps and Treatment Strategy Roadmaps for personalized cancer care, announced today that the company has entered into a strategic collaboration with Foundation Medicine, Inc.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/n-of-one-announces-agreement-with-foundation-medicine-to-provide-the-first-patient-specific-genomic-diagnostic.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[35],"tags":[],"class_list":["post-46025","post","type-post","status-publish","format-standard","hentry","category-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/46025"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=46025"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/46025\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=46025"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=46025"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=46025"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}